- Home
- ANTX vs IGC Comparison
ANTX vs IGC Comparison
Compare ANTX & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANTX
- IGC
- Stock Information
- Founded
- ANTX 2017
- IGC 2005
- Country
- ANTX United States
- IGC United States
- Employees
- ANTX N/A
- IGC N/A
- Industry
- ANTX Biotechnology: Pharmaceutical Preparations
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- ANTX Health Care
- IGC Health Care
- Exchange
- ANTX Nasdaq
- IGC Nasdaq
- Market Cap
- ANTX 34.4M
- IGC 39.8M
- IPO Year
- ANTX 2022
- IGC N/A
- Fundamental
- Price
- ANTX $1.12
- IGC $0.39
- Analyst Decision
- ANTX Buy
- IGC Strong Buy
- Analyst Count
- ANTX 2
- IGC 2
- Target Price
- ANTX $2.00
- IGC $4.00
- AVG Volume (30 Days)
- ANTX 66.7K
- IGC 968.4K
- Earning Date
- ANTX 11-12-2025
- IGC 11-14-2025
- Dividend Yield
- ANTX N/A
- IGC N/A
- EPS Growth
- ANTX N/A
- IGC N/A
- EPS
- ANTX N/A
- IGC N/A
- Revenue
- ANTX N/A
- IGC $1,327,000.00
- Revenue This Year
- ANTX N/A
- IGC $3.54
- Revenue Next Year
- ANTX N/A
- IGC $15.12
- P/E Ratio
- ANTX N/A
- IGC N/A
- Revenue Growth
- ANTX N/A
- IGC 24.95
- 52 Week Low
- ANTX $0.98
- IGC $0.25
- 52 Week High
- ANTX $1.68
- IGC $0.50
- Technical
- Relative Strength Index (RSI)
- ANTX 38.88
- IGC 45.99
- Support Level
- ANTX $1.12
- IGC $0.38
- Resistance Level
- ANTX $1.24
- IGC $0.45
- Average True Range (ATR)
- ANTX 0.07
- IGC 0.02
- MACD
- ANTX -0.01
- IGC -0.00
- Stochastic Oscillator
- ANTX 4.03
- IGC 35.52
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.